$CSDX CS Diagnostics Corp. is Entering into a $5 M
Post# of 34
(Total Views: 46)
Posted On: 04/15/2025 10:51:16 AM
$CSDX CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
https://www.accessnewswire.com/newsroom/en/he...th-1014921
CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.
The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets.
Strategic Purpose:
The intended use of funds will be allocated to support the commercial rollout of CS- Protect Hydrogel further R&D, operational expansions, and U.S. EPA approval for its Smart Disinfectant Product MEDUSA. The parties will proceed with final due diligence and definitive agreement negotiations with the goal of closing the transaction in the coming weeks.
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"This funding agreement will mark a significant milestone in strengthening our financial foundation and aligning with a strategic financial capability. It will allow us to confidently advance through key regulatory stages and operates in several markets while preserving shareholder value and minimizing dilution."
https://www.accessnewswire.com/newsroom/en/he...th-1014921
CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.
The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets.
Strategic Purpose:
The intended use of funds will be allocated to support the commercial rollout of CS- Protect Hydrogel further R&D, operational expansions, and U.S. EPA approval for its Smart Disinfectant Product MEDUSA. The parties will proceed with final due diligence and definitive agreement negotiations with the goal of closing the transaction in the coming weeks.
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"This funding agreement will mark a significant milestone in strengthening our financial foundation and aligning with a strategic financial capability. It will allow us to confidently advance through key regulatory stages and operates in several markets while preserving shareholder value and minimizing dilution."
(0)
(0)CS Diagnostics Corp. (CSDX) Stock Research Links
Scroll down for more posts ▼